CDNA - CareDx, Inc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
31.73
-0.17 (-0.53%)
As of 1:27PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close31.90
Open31.97
Bid31.77 x 900
Ask31.75 x 1100
Day's Range31.57 - 32.52
52 Week Range10.31 - 39.38
Volume160,498
Avg. Volume944,563
Market Cap1.336B
Beta (3Y Monthly)1.00
PE Ratio (TTM)N/A
EPS (TTM)-1.17
Earnings DateAug 8, 2017 - Aug 14, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est43.40
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    CareDx to Participate in Upcoming Conferences

    BRISBANE, Calif., May 22, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • Thomson Reuters StreetEvents8 days ago

    Edited Transcript of CDNA earnings conference call or presentation 8-May-19 8:30pm GMT

    Q1 2019 CareDx Inc Earnings Call

  • GlobeNewswire10 days ago

    CareDx applauds HHS Report on Cost Savings of Lifetime Immunosuppressive Drug Coverage for Transplant Patients

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, applauds the Department of Health and Human Services for releasing a report highlighting the cost savings of lifetime immunosuppressive drug coverage for transplant patients. CareDx is dedicated to improving the long-term health outcomes of transplant recipients. A critical part of protecting a donated kidney is appropriate dosage of immunosuppressant drugs for the life of the recipient, treatment financially out of reach for many individuals without insurance coverage.

  • Here's Why CareDx Stock Is Rising Today
    Motley Fool15 days ago

    Here's Why CareDx Stock Is Rising Today

    The transplant diagnostic service provider took some important steps forward in the first quarter.

  • CareDx, Inc (CDNA) Q1 2019 Earnings Call Transcript
    Motley Fool16 days ago

    CareDx, Inc (CDNA) Q1 2019 Earnings Call Transcript

    CDNA earnings call for the period ending March 31, 2019.

  • CareDx (CDNA) Q1 Earnings and Revenues Top Estimates
    Zacks16 days ago

    CareDx (CDNA) Q1 Earnings and Revenues Top Estimates

    CareDx (CDNA) delivered earnings and revenue surprises of 350.00% and 7.07%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press16 days ago

    CareDx: 1Q Earnings Snapshot

    On a per-share basis, the Brisbane, California-based company said it had a loss of 18 cents. Earnings, adjusted for stock option expense and non-recurring costs, came to 5 cents per share. The results ...

  • GlobeNewswire16 days ago

    CareDx Reports First Quarter 2019 Results

    BRISBANE, Calif., May 08, 2019 -- CareDx, Inc. (NASDAQ: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire17 days ago

    CareDx’s AlloSeq cfDNA and QTYPE Solutions Featured at EFI 2019

    BRISBANE, Calif., May 07, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.

  • The CareDx (NASDAQ:CDNA) Share Price Is Up 580% And Shareholders Are Delighted
    Simply Wall St.18 days ago

    The CareDx (NASDAQ:CDNA) Share Price Is Up 580% And Shareholders Are Delighted

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Investing can be hard but the potential fo an individual stock to pay off big time inspires us...

  • Hedge Funds Have Never Been This Bullish On CareDx, Inc. (CDNA)
    Insider Monkey21 days ago

    Hedge Funds Have Never Been This Bullish On CareDx, Inc. (CDNA)

    Before we spend days researching a stock idea we'd like to take a look at how hedge funds and billionaire investors recently traded that stock. S&P 500 Index ETF (SPY) lost 13.5% in the fourth quarter. Seven out of 11 industry groups in the S&P 500 Index were down more than 20% from their 52-week […]

  • GlobeNewswire21 days ago

    AlloMap In-Network with Anthem Blue Cross

    BRISBANE, Calif., May 03, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically.

  • GlobeNewswire22 days ago

    CareDx Adds iBox Technology, Next Step Towards Artificial Intelligence in Transplant Care

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced a partnership with Cibiltech, a French MedTech company that develops AI-based products for predictive medicine, to commercialize Predigraft. Predigraft is a data analysis tool that provides an early prediction of an individual’s risk of allograft rejection and transplant loss. It was developed from Cibiltech’s proprietary software algorithm called iBox, which is built off the outcomes data from tens of thousands of transplant patients.

  • CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
    Zacks23 days ago

    CareDx (CDNA) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

    CareDx (CDNA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • GlobeNewswire29 days ago

    CareDx Agrees to Acquire OTTR Complete Transplant Management

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients,  today announced it has agreed to acquire OTTR Complete Transplant Management (“OTTR”), the leading provider of organ transplant patient tracking software. OTTR provides comprehensive solutions for transplant patient management, which are currently used in over 60 leading transplant centers in the US.

  • GlobeNewswirelast month

    CareDx to Announce First Quarter 2019 Financial Results on May 8th, 2019

    BRISBANE, Calif., April 23, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients,.

  • Breakeven On The Horizon For CareDx, Inc (NASDAQ:CDNA)
    Simply Wall St.last month

    Breakeven On The Horizon For CareDx, Inc (NASDAQ:CDNA)

    CareDx, Inc's (NASDAQ:CDNA): CareDx, Inc., a transplant diagnostics company, together with its subsidiaries, focuses on the discovery, development, and commercialization of diagnostic solutions for transplant patients worldwide...

  • GlobeNewswirelast month

    CareDx Accuses Natera of False Advertising Claims That Mislead Medical Personnel and Transplant Patients

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on creating diagnostic solutions for organ transplant patients, has filed a second lawsuit against Natera, Inc. in the United States District Court for Delaware. In this suit, CareDx alleges that Natera’s comparisons of its kidney transplant technology to CareDx’s AlloSure technology are based on numerous unscientific, unreliable, and inappropriate conclusions, and are therefore misleading.

  • GlobeNewswire2 months ago

    Cutting-Edge HeartCare and AlloMap Solutions Featured at ISHLT 2019

    BRISBANE, Calif., April 03, 2019 -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics company focused on the discovery, development, and commercialization of.

  • A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing
    TechCrunch2 months ago

    A new lawsuit involving Stanford and Sequoia Capital highlights fights to come over cell-free DNA testing

    This morning, a publicly traded transplant diagnostics company called CareDx,along with Stanford University, sued another publicly traded genetic testingcompany, Natera, for patent infringement

  • GlobeNewswire2 months ago

    CareDx Files Patent Infringement Lawsuit Against Natera

    CareDx, Inc. (CDNA), a leading molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it has filed a patent infringement suit against Natera, Inc., in the United States District Court for Delaware.  CareDx is asserting U.S. Patent Nos. 9,845,497 and 8,703,652, that are exclusively licensed to CareDx from Stanford University.  Stanford is joined in the suit as a necessary party because it is the registered owner of these patents.  These patents cover non-invasive monitoring of organ transplant rejection through cell-free DNA analysis.

  • GlobeNewswire2 months ago

    Market Trends Toward New Normal in Louisiana-Pacific, The Michaels Companies, VEREIT, CymaBay Therapeutics, CareDx, and Harsco — Emerging Consolidated Expectations, Analyst Ratings

    NEW YORK, March 25, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire2 months ago

    Cedars Sinai Uses AlloSure in Tocilizumab Trial

    CareDx, Inc. (CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announces a partnership with the Cedars-Sinai Comprehensive Transplant Center to study the use of AlloSure to characterize response to therapy in kidney transplant recipients that are being treated for chronic antibody-mediated rejection (ABMR). ABMR is recognized as the leading cause of late kidney transplant failure. Long-term graft survival has not improved, primarily due to late diagnosis and lack of effective therapeutic options.

  • These Factors Make CareDx, Inc (NASDAQ:CDNA) An Interesting Investment
    Simply Wall St.2 months ago

    These Factors Make CareDx, Inc (NASDAQ:CDNA) An Interesting Investment

    As an investor, I look for investments which does not compromise one fundamental factor for another. By this I mean, I look at stocks holistically, from their financial health toRead More...

  • Cisco Leads 5 Top Stocks Flexing Strength In Struggling Market
    Investor's Business Daily2 months ago

    Cisco Leads 5 Top Stocks Flexing Strength In Struggling Market

    Cisco stock and Planet Fitness stock lead five top stocks showing relative strength amid the market pullback.